MHCEpitopeEnergy, a Flexible Rosetta-Based Biotherapeutic Deimmunization Platform
暂无分享,去创建一个
Chris Bailey-Kellogg | Vikram Khipple Mulligan | Sagar D. Khare | Brahm J. Yachnin | C. Bailey-Kellogg | S. Khare | V. Mulligan | B. Yachnin
[1] D. Baker,et al. RosettaHoles: Rapid assessment of protein core packing for structure prediction, refinement, design, and validation , 2008, Protein science : a publication of the Protein Society.
[2] Gajendra P. S. Raghava,et al. ProPred: prediction of HLA-DR binding sites , 2001, Bioinform..
[3] J. Chamberlain,et al. Cas9 immunity creates challenges for CRISPR gene editing therapies , 2018, Nature Communications.
[4] L. Swint-Kruse. Using Evolution to Guide Protein Engineering: The Devil IS in the Details. , 2016, Biophysical journal.
[5] Ramgopal R. Mettu,et al. CD4+ T-cell epitope prediction using antigen processing constraints. , 2016, Journal of immunological methods.
[6] J. Greenbaum,et al. Improved methods for predicting peptide binding affinity to MHC class II molecules , 2018, Immunology.
[7] Chris Bailey-Kellogg,et al. Structure‐based redesign of proteins for minimal T‐cell epitope content , 2013, J. Comput. Chem..
[8] Robert M. Stroud,et al. Efficiency of signalling through cytokine receptors depends critically on receptor orientation , 1998, Nature.
[9] Jens Meiler,et al. RosettaScripts: A Scripting Language Interface to the Rosetta Macromolecular Modeling Suite , 2011, PloS one.
[10] Chris Bailey-Kellogg,et al. Computationally optimized deimmunization libraries yield highly mutated enzymes with low immunogenicity and enhanced activity , 2017, Proceedings of the National Academy of Sciences.
[11] Bjoern Peters,et al. Functional classification of class II human leukocyte antigen (HLA) molecules reveals seven different supertypes and a surprising degree of repertoire sharing across supertypes , 2011, Immunogenetics.
[12] Bjoern Peters,et al. Molecular Determinants of T Cell Epitope Recognition to the Common Timothy Grass Allergen , 2010, The Journal of Immunology.
[13] Russ B. Altman,et al. Predicting HLA class II antigen presentation through integrated deep learning , 2019, Nature Biotechnology.
[14] Thomas L. Madden,et al. Improving the accuracy of PSI-BLAST protein database searches with composition-based statistics and other refinements. , 2001, Nucleic acids research.
[15] Sergey Lyskov,et al. PyRosetta: a script-based interface for implementing molecular modeling algorithms using Rosetta , 2010, Bioinform..
[16] M. Nielsen,et al. Structural Properties of MHC Class II Ligands, Implications for the Prediction of MHC Class II Epitopes , 2010, PloS one.
[17] C. D. Ranter,et al. Three-dimensional structure of staphylokinase, a plasminogen activator with therapeutic potential , 1997, Nature Structural Biology.
[18] Frans Van de Werf,et al. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. , 1993, The New England journal of medicine.
[19] T. Terwilliger,et al. Engineering and characterization of a superfolder green fluorescent protein , 2006, Nature Biotechnology.
[20] Zuben E Sauna,et al. Evaluating and Mitigating the Immunogenicity of Therapeutic Proteins. , 2018, Trends in biotechnology.
[21] Ronit Mazor,et al. Identification and elimination of an immunodominant T-cell epitope in recombinant immunotoxins based on Pseudomonas exotoxin A , 2012, Proceedings of the National Academy of Sciences.
[22] Timothy A. Whitehead,et al. Computational Design of Proteins Targeting the Conserved Stem Region of Influenza Hemagglutinin , 2011, Science.
[23] M. Weisman,et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. , 2003, Arthritis and rheumatism.
[24] C. Bailey-Kellogg,et al. Globally deimmunized lysostaphin evades human immune surveillance and enables highly efficacious repeat dosing , 2020, Science Advances.
[25] Jens Keilwagen,et al. PRROC: computing and visualizing precision-recall and receiver operating characteristic curves in R , 2015, Bioinform..
[26] William S. Lane,et al. Predominant naturally processed peptides bound to HLA-DR1 are derived from MHC-related molecules and are heterogeneous in size , 1992, Nature.
[27] Lindong Weng,et al. Droplet Microfluidics-Enabled High-Throughput Screening for Protein Engineering , 2019, Micromachines.
[28] Jaime Prilusky,et al. Automated Structure- and Sequence-Based Design of Proteins for High Bacterial Expression and Stability , 2016, Molecular cell.
[29] Karl E Griswold,et al. EpiSweep: Computationally Driven Reengineering of Therapeutic Proteins to Reduce Immunogenicity While Maintaining Function. , 2017, Methods in molecular biology.
[30] A. Schwan,et al. Exotoxin A–eEF2 complex structure indicates ADP ribosylation by ribosome mimicry , 2005, Nature.
[31] A. Rudensky,et al. Sequence analysis of peptides bound to MHC class II molecules , 1991, Nature.
[32] E. Topol,et al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. , 2003, JAMA.
[33] Roland L. Dunbrack,et al. The Rosetta all-atom energy function for macromolecular modeling and design , 2017, bioRxiv.
[34] M. Pirmohamed,et al. Immunogenicity to Biologics: Mechanisms, Prediction and Reduction , 2012, Archivum Immunologiae et Therapiae Experimentalis.
[35] G. S. Pandey,et al. Post hoc assessment of the immunogenicity of bioengineered factor VIIa demonstrates the use of preclinical tools , 2017, Science Translational Medicine.
[36] John Sidney,et al. Rationally Engineered Therapeutic Proteins with Reduced Immunogenicity , 2005, The Journal of Immunology.
[37] Marc De Maeyer,et al. Elimination of a Human T-cell Region in Staphylokinase by T-cell Screening and Computer Modeling , 2002, Thrombosis and Haemostasis.
[38] Jason W. Labonte,et al. Ensuring scientific reproducibility in bio-macromolecular modeling via extensive, automated benchmarks , 2021, Nature Communications.
[39] David E. Golan,et al. Protein therapeutics: a summary and pharmacological classification , 2008, Nature Reviews Drug Discovery.
[40] Todd M. Allen,et al. Humanized immune system mouse models: progress, challenges and opportunities , 2019, Nature Immunology.
[41] Development and validation of a broad scheme for prediction of HLA class II restricted T cell epitopes. , 2015, Journal of immunological methods.
[42] George Coukos,et al. Robust prediction of HLA class II epitopes by deep motif deconvolution of immunopeptidomes , 2019, Nature Biotechnology.
[43] Alessandro Sette,et al. The Immune Epitope Database (IEDB): 2018 update , 2018, Nucleic Acids Res..
[44] Z. Sauna,et al. Mitigation of T-cell dependent immunogenicity by reengineering factor VIIa analogue. , 2019, Blood advances.
[45] Xavier Robin,et al. pROC: an open-source package for R and S+ to analyze and compare ROC curves , 2011, BMC Bioinformatics.
[46] David Baker,et al. Comprehensive computational design of ordered peptide macrocycles , 2017, Science.
[47] Andrew D Ellington,et al. Synthetic DNA Synthesis and Assembly: Putting the Synthetic in Synthetic Biology. , 2017, Cold Spring Harbor perspectives in biology.
[48] Brian D. Weitzner,et al. Macromolecular modeling and design in Rosetta: recent methods and frameworks , 2020, Nature Methods.
[49] David Baker,et al. Removing T-cell epitopes with computational protein design , 2014, Proceedings of the National Academy of Sciences.
[50] Zuben E. Sauna,et al. Recent advances in (therapeutic protein) drug development , 2017, F1000Research.
[51] Chris Bailey-Kellogg,et al. Structure-Guided Deimmunization of Therapeutic Proteins , 2012, RECOMB.
[52] Jason W. Labonte,et al. Computationally designed peptide macrocycle inhibitors of New Delhi metallo-β-lactamase 1 , 2021, Proceedings of the National Academy of Sciences.
[53] D. Baker,et al. Global analysis of protein folding using massively parallel design, synthesis, and testing , 2017, Science.